Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Grand Pharmaceutical Group's Enterprise Value is $3,100.04 Mil.
Grand Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $211.30 Mil. Therefore, Grand Pharmaceutical Group's EV-to-EBIT ratio for today is 14.67.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Grand Pharmaceutical Group (OTCPK:CGPHF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Grand Pharmaceutical Group's EV-to-EBIT for today is
Grand Pharmaceutical Group's current Enterprise Value is $3,100.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $211.30 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Grand Pharmaceutical Group's EV-to-EBITDA for today is:
Grand Pharmaceutical Group's current Enterprise Value is $3,100.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $211.30 Mil.
Grand Pharmaceutical Group's current Enterprise Value is $3,100.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $1,571.88 Mil.
Grand Pharmaceutical Group's current Enterprise Value is $3,100.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $211.92 Mil.
Grand Pharmaceutical Group's current Enterprise Value is $3,100.04 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $16.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group Enterprise Value Related Terms
Grand Pharmaceutical Group Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Enterprise Value falls into.
Grand Pharmaceutical Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Grand Pharmaceutical Group's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of $3,100.04 Mil mean?
Grand Pharmaceutical Group (CGPHF) has a Enterprise Value of $3,100.04 Mil as of Jun. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's Enterprise Value too high?
Grand Pharmaceutical Group's current Enterprise Value is $3,100.04 Mil. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Enterprise Value compare to ZTS?
Grand Pharmaceutical Group's Enterprise Value of $3,100.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current Enterprise Value is $3,100.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Enterprise Value of $3,100.04 Mil. The current Enterprise Value is $3,100.04 Mil. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Enterprise Value is $3,100.04 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 